Basilea Pharmaceutica AG
XBER:PK5
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Basilea Pharmaceutica AG
XBER:PK5
|
CH |
|
P
|
Pampa Metals Corp
CNSX:PM
|
CA |
|
Reebonz Holding Ltd
OTC:RBZHF
|
SG |
Wall St Price Targets
PK5 Price Targets Summary
Basilea Pharmaceutica AG
According to Wall Street analysts, the average 1-year price target for PK5 is 49.92 EUR with a low forecast of 35.19 EUR and a high forecast of 62.71 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is PK5's stock price target?
Price Target
49.92
EUR
According to Wall Street analysts, the average 1-year price target for PK5 is 49.92 EUR with a low forecast of 35.19 EUR and a high forecast of 62.71 EUR.
What is the Revenue forecast for Basilea Pharmaceutica AG?
Projected CAGR
2%
Over the last 13 years, the compound annual growth rate for Revenue has been 11%. The projected CAGR for the next 5 years is 2%.
What is the Gross Profit forecast for Basilea Pharmaceutica AG?
Projected CAGR
2%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 10%. The projected CAGR for the next 5 years is 2%.
What is the Operating Income forecast for Basilea Pharmaceutica AG?
Projected CAGR
13%
The compound annual growth rate for Operating Income over the next 5 years is 13%.
What is the Pre-Tax Income forecast for Basilea Pharmaceutica AG?
Projected CAGR
-22%
The compound annual growth rate for Pre-Tax Income over the next 3 years is -22%.
What is the Net Income forecast for Basilea Pharmaceutica AG?
Projected CAGR
17%
The compound annual growth rate for Net Income over the next 5 years is 17%.
